Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study
Journal of Cystic Fibrosis · 2026-09 · 25 (5) · 778-785
DOI: 10.1016/j.jcf.2026.05.014 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Cystic Fibrosis, 2026-09. Verfasst von Jennifer L Goralski und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Canadian Institutes of Health Research, Canada Foundation for Innovation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Elexacaftor/tezacaftor/ivacaftor(ELX/TEZ/IVA) was safe and efficacious in children with CF 2-5y with at least one F508del allele in 24-week phase 3 Trial 445-111. Children who completed 445-111 were eligible for the long-term safety and efficacy extension trial. METHODS: This 2-part (part A and B), open-label, phase 3, 192-week trial enrolled children ≥ 2y who completed 445-111. PRIMARY ENDPOINT: safety and tolerability. Secondary endpoints: absolute changes in sweat chloride(SwCl) concentration and lung clearance index 2.5(LCI2.5). 96-week analysis (Part A) is reported. RESULTS: Seventy children received ELX/TEZ/IVA and mean exposure was 89.9 (SD: 17.0) weeks. All children had ≥1 adverse event(AE), most AEs were mild (35.7%) or moderate (52.9%) in severity. Most AEs were generally consistent with known manifestations of CF in children. Fifteen children had ≥1 serious AE, of which 1 (DIOS) was considered related to ELX/TEZ/IVA. Three children discontinued due to AEs. Decreases in SwCl (-57.0 mmol/L [95%CI: -61.5, -52.6]) and LCI2.5 (-0.90 [95%CI: -1.14, -0.67]) were sustained from parent trial baseline, 80.8% of children achieved SwCl
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- University of Arizona, Tucson, Arizona, USA.
- Washington University School of Medicine, St. Louis, Missouri, USA.
- University of British Columbia and British Columbia Children's Hospital Vancouver, British Colombia, Canada.
- The Royal Children's Hospital, Murdoch Children's Institute, and Department of Pediatrics, University of Melbourne, Parkville, Victoria, Australia.
- Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Förderung
- Deutsche Forschungsgemeinschaft
- Canadian Institutes of Health Research
- Canada Foundation for Innovation
- University of British Columbia
- National Institutes of Health
- European Respiratory Society
- BC Children's Hospital
- Bundesministerium für Forschung, Technologie und Raumfahrt
Zitieren
APA
Goralski, J. L., Daines, C., Pittman, J. E., Rayment, J. H., Robinson, P., Thursfield, R., Stehling, F., Ratjen, F., Ahluwalia, N., Shi, P., Lu, M., Weinstock, T. G., Mall, M. A., & VX20-445-112 Study Group (2026). Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study. Journal of Cystic Fibrosis, 25(5), 778-785. https://doi.org/10.1016/j.jcf.2026.05.014
Vancouver
Goralski JL, Daines C, Pittman JE, Rayment JH, Robinson P, Thursfield R, et al. Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study. Journal of Cystic Fibrosis. 2026;25(5):778-785. doi:10.1016/j.jcf.2026.05.014
BibTeX
@article{Goralski2026,
author = {Goralski, Jennifer L and Daines, Cori and Pittman, Jessica E and Rayment, Jonathan H and Robinson, Philip and Thursfield, Rebecca and Stehling, Florian and Ratjen, Felix and Ahluwalia, Neil and Shi, Peng and Lu, Mengdi and Weinstock, Tanya G and Mall, Marcus A and VX20-445-112 Study Group, VX20-445-112 Study Group},
title = {Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {5},
pages = {778--785},
doi = {10.1016/j.jcf.2026.05.014}
}
EUVIMED